Background
Lung neuroendocrine tumors (NET) comprise the four histotypes typical carcinoid (TC), atypical carcinoid (AC), large cell neuroendocrine carcinoma (LCNEC) and small cell lung carcinoma (SCLC). In comparison to the carcinoids, LCNEC and SCLC are aggressive malignancies with much higher loss of growth control, due to e.g. loss of tumor suppressors, including protein phosphatase and tensin homolog (PTEN) [
1,
2].
The
PTEN gene is located on chromosome 10q23.3, encoding a 403 amino acid residue protein [
3]. There is no alternative protein and cells thus are ultrasensitive to subtle dosage alterations, referred to as quasi- or haploinsufficiency [
4]. PTEN is a protean protein with a dual-specificity cytosolic lipid and tyrosine phosphatase activity. Both own phosphorylation status and direct protein-protein interactions are increasingly investigated [
5]. Recently, a secreted PTEN Long variant was detected [
6]. These pleiotropic effects are regulated by multiple layers of non-genetic regulation, including epigenetic silencing and post-transcriptional regulation by post-translational modifications (PTM) and non-coding RNAs [
7].
Nuclear PTEN was originally detected by immunohistochemistry (IHC) using monoclonal antibody 6H2.1 [
8]: E.g. normal pancreatic islet cells exhibited predominantly nuclear immunoreactivity, whereas endocrine pancreatic tumors had a cytosolic expression pattern [
9]. This led to the concept that in normal cells PTEN is rather nuclear, but in neoplastic it is cytosolic. Various functions were attributed to nuclear PTEN, coining the term “guardian of the genome” for it. They include protein association to the centromere-specific binding protein C (CENP-C) favoring chromosomal stability, to Rad51/52 favoring DNA double strand break repair, to p300 favoring high acetylation of p53, to p73 favoring apoptosis and to the anaphase-promoting complex/cyclosome (APC/C) favoring cell cycle arrest [
10-
15].
The protein shuttling between nucleus and cytosol is dependent on two PTM: Ubiquitinylation and sumoylation. First, PTEN is ubiquitinylated by NEDD4-1 (neural precursor cell expressed developmentally downregulated 4–1) as the main E3 ubiquitin ligase. NEDD4-1 is regulated by cofactors NDFIP1 (NEDD4 family-interacting protein 1) and p34 [
16-
19]. PTEN mono-ubiquitinylation resulted in nuclear import, whereas poly-ubiquitinylation caused proteasome-mediated degradation [
20]. USP7 (herpes virus-associated ubiquitin-specific protease, HAUSP) and USP13 are PTEN deubiquitinylases (DUBs) [
21-
23]. Second, PTEN sumoylated by small ubiquitin-related modifier proteins (SUMO) is again nuclear. Lysine residues 254 and 266 as well as the mono-ubiquitinylation site 289 in the C2 domain are SUMO acceptors [
24-
26] and PIASxα is a new SUMO E3 ligase [
27]. No data exists so far about PTEN desumoylases but members of the SENP family are most likely involved [
28].
In this study we investigated the compartmentalization of the PTEN protein in nucleus versus cytosol of lung NET in a multicenter TMA cohort together with the USP7 and the SUMO2/3 protein immunoreactivity as read-outs for cellular ubiquitinylation and sumoylation, respectively. Results were correlated with the PTEN and p53 genomic status determined by fluorescence in-situ hybridization (FISH), with clinico-pathologic data including overall survival and with lung NET diagnostic markers.
Methods
Patients and tissue samples
One hundred and ninety-two patients with surgically resected (n = 183) or autopsy diagnosed (n = 9) neuroendocrine tumours of the lung between 1993 and 2007 at the University Hospital Zurich (n = 90), the Technical University of Munich (n = 73) and the Triemli Hospital Zurich (n = 29) were retrospectively retrieved from the computer databases and enrolled in this study. The study was approved by the Institutional Ethical Review Board of the University Hospital Zurich (reference number StV 29-2009/14).
Tissue microarray construction
The TMA construction was accomplished with a semiautomatic tissue arrayer (Beecher Instruments, Sun Prairie, WI, USA). One or two most representative tumor areas were chosen and two tissue cores of 0.6 mm diameter assembled into the recipient paraffin blocks. Additional cores of control tissue, including normal lung as well as neuroendocrine tumors of the uterus, the ileo-caecum and the appendix were added. Four micrometer thick sections were transferred to an adhesive-coated slide system (Instrumedics, Hackensack, NJ, USA).
Immunohistochemistry
For PTEN, the automated Leica Bond® IHC platform (Vision Biosystems, Melbourne, AUS) was used. After boiling in Tris pH 8 containing buffer H2 for 30 min, the slide was incubated for 30 min at RT with the mouse monoclonal anti-PTEN ab clone 6H2.1 (1:200 dilution, DAKO-Cytomation, Glostrup, DK). Detection was performed using the Refine-DAB Bond kit. For SUMO2/3 and USP7, the Ventana Benchmark® platform (Ventana Medical Systems, Tucson, AZ, USA) was used. The cell conditioner 1 standard mono protocol (CC1-mono) was performed: pre-treatment with boiling for 60 min in pH 8 Tris buffer following incubation with rabbit polyclonal anti-SUMO2/3 ab clone 3742 (1:500 dilution, Abcam, Cambridge, UK) or rabbit polyclonal anti-USP7 ab clone TFE1 (1:400 dilution, Bethyl Laboratories, Inc., Montgomery, TX, USA) for 60 min at RT. Detection was done with the UltraMap rabbit DAB kit. For MIB-1, synaptophysin, chromogranin A and TTF-1 our diagnostic protocols were used.
Nuclear and cytosolic immunoreactivities of PTEN, SUMO2/3 and USP7 were scored for intensity and frequency. PTEN was independently scored by two investigators (S.C. and A.S.) in a blinded manner. The intensity was semi-quantitatively scored 0 (negative), 1 (weak), 2 (moderate) or 3 (strong). The percentage of positive cells was proportionally scored 0 (0%), 10 (1-10%), 50 (11-50%) or 100 (>50%). The H-score was obtained by multiplication of intensity with percentage (range 0 to 300), summed up for the two cores and divided by two.
Fluorescence in-situ hybridization
For PTEN, a dual colour probe for cytoband 10q23 and region 10p11.1-q11.1 (Vysis LSI PTEN Spectrum-Orange and CEP10 Spectrum-Green, Abbott AG, Baar, CH) was used. For p53, a dual colour probe for cytoband 17p13.1 (172 kb) and region 17p11.1-q11.1 (also Vysis) was used. For each case, 100 non-overlapping nuclei were evaluated using an Olympus fluorescence microscope with a 100-fold magnification objective. Tumors with <100 assessable nuclei were excluded. Normal PTEN/CEP10 and p53/CEP17 ratios were set at 1.
Statistical analysis
Analyses were computed using the IBM SPSS 22 statistics software. Correlations of H- or FISH scores with histology or among each other were assessed by Kendall’s tau-b tests, using non-dichotomized data. Inter-observer agreement between S.C. and A.S. was controlled with Cohen’s kappa coefficient. Dunnett T3 post-hoc tests were used to assess differences in ∆H-score means between histotypes two by two. Survival data was obtained from 156 surgical patients. Patients having an OS <1 month or autopsy cases (n = 9) were excluded. Tumor-specific survival of carcinoids was not fully assessable. Markers were dichotomized closest to the median (for all tumors and for SCLC only) and OS analyzed by univariate Cox regressions and by the Kaplan-Meier method using log rank tests. A p-value <0.05 was considered significant.
Discussion
In this study, we show that PTEN protein is expressed in both nucleus and cytosol of lung NET. In comparison to carcinoids, LCNEC/SCLC presented a protein loss in both compartments concomitant with loss of the PTEN and p53 genes. The PTEN loss correlated with a loss of nuclear USP7. In contrast, high grade lung NET presented an increase of sumoylation.
There is a lack of standardization for a best practice PTEN IHC protocol and nuclear immunoreactivity as reported in endocrine pancreatic tumors and thyroid [
29,
30] was originally considered an artefact. In 2005, Pallares et al. tested 4 different clones on endometrial carcinomas, including a polyclonal and the monoclonals 28H6, 10P03 and 6H2.1. 6H2.1 was the only one to show a correlation between immunoreactivity and
PTEN gene alterations such as mutation, deletion or promoter methylation [
8]. This is corroborated by 2 new studies in prostate and renal cell as well as endometrial carcinoma [
31,
32] which propose 6H2.1 as the antibody of choice, demonstrating excellent sensitivity for both nuclear and cytoplasmic staining, specificity for PTEN immunoblot and good correlation with PTEN FISH status with regard to nuclear staining. Moreover, a recent follow-up to the Pallares study by Maiques et al. analysed the relevant analytical and preanalytical variables for PTEN IHC using 6H2.1 and DAKO-based reagents [
33].
PTEN expression in normal cells such as alveolar wall pneumocytes or stromal fibroblasts is predominantly nuclear (Figure
1A), corroborating the concept that in non-neoplastic cells, the protein fulfils rather nuclear functions. Taking together the scores of 2 observers, the H-score presented a five-fold range (maximum 248 in TC, PTEN cytosol A.S. and minimum 49 in SCLC, PTEN nuclear S.C.). For a haplo-insufficient protein, this may fit well with the different behaviour of a TC versus a SCLC.
The PTEN protein loss correlated with a nuclear USP7 loss, indicating a reduction of de-ubiquitinylation, thus an increase of poly-ubiquitinylated enzyme targeted for proteasome degradation. USP7 also removes ubiquitin from p53 and the p53 E3 ubiquitin ligase MDM2 [
34], therefore is a functional dose regulator of two important tumor suppressors. The regulation of USP7 in tumor cell proliferation seems to be organ-specific. In prostate carcinoma, both USP7 and MDM4 overexpression were associated with tumor aggressiveness, while both up- and down-regulation was found to inhibit colon carcinoma cell proliferation due to enhanced degradation of MDM2 following constitutively elevated p53 levels [
21,
35,
36].
In contrast to PTEN and USP7, the expression of SUMO2/3 globally increased in the high grade tumors. These results may be explained by a concept of differential sumoylation among lung NET and/or a potential sequestration mechanism. Sequestration of nuclear PTEN was described for protein phosphatase-1 nuclear targeting subunit (PNUTS, PPP1R10) [
37]. Another model indicated conformationally-dependent cytoplasmic retention and negative regulation of nuclear PTEN activity by oncogenic cytoplasmic p27Kip1 [
38,
39].
Both PTEN and p53 are sumoylated proteins that can be identified in SUMO-traps using SUMO interacting motifs (SIMs) [
40]. PTEN undergoes complex interactions in the nucleus with p53, stimulating p300-mediated p53 acetylation following tetramerization [
10] as well as with the p53 family member p73 [
13]. Inversely, p53 can up- or downregulate PTEN, e.g. via caspase-mediated degradation [
41,
42]. p53 itself is ubiquitinylated by MDM2 [
43,
44]. It remains to be seen how ubiquitinylation and/or sumoylation affect PTEN-p53 interaction. There is also crosstalk between sumoylation and ubiquitinylation: E.g. the SUMO E3 ligase PIASxα enhanced PTEN protein stability by reducing its ubiquitinylation [
27] and PTEN-SUMO1 showed a reduced capacity to form covalent interactions with mono-ubiquitin [
25].
How the post-translationally modified PTEN protein, including PTEN-SUMO, −Ub and potentially -Ac, −P or -OC (open conformation)-p27 shuttles between nucleus and cytosol is unclear [
45,
46]. The protein lacks a true nuclear localization signal. Different mechanisms were proposed for this shuttling including simple diffusion through nuclear pores [
47], active RAN-mediated nuclear import [
48] and transport via the major vault protein (MVP) [
49].
The histopathologic diagnosis between TC and AC is notoriously difficult to be made. Indeed, there is a trend to pool them into carcinoids and secondarily stratify them according to molecular data. This view is corroborated by the similar survivals curves on Figure
2. In our opinion, the entity “atypical carcinoid” may simply arise by the fact that enlarging carcinoids have a higher mitotic rate and more necrotic foci. These data need however to be interpreted with caution, since OS and not tumor-specific survival was computed. This is of significant importance for mainly indolent tumors such as carcinoids. For this same reason, we did not perform a subgroup analysis among carcinoids. However, the correlation with the other clinico-pathologic parameters showed that a PTEN loss is primarily found in male with TTF-1 negative larger carcinoids.
Differences between LCNEC and SCLC are also debated. SCLC cells have a size less than the diameter of 3 small resting lymphocytes, but interspersed larger elements are often observed. All markers apart nuclear and cytosolic PTEN of scorer S.C. failed to distinguish them and no survival differences were found. The survival results favour a concept of single high-grade lung NET [
50]. Among SCLC, we identified a subset in which high cytosolic PTEN, high nuclear and cytosolic SUMO2/3, high synaptophysin and high TTF1 were associated with better survival. As observed in the carcinoids as well, these results are best interpreted as tumor dedifferentiation being associated with loss of respective tumor suppressor and differentiation markers.
From a therapeutic point of view, loss of PTEN leaves cells sensitive to DNA damage, but it also provides a PI3K pathway survival signal, the inhibition of which could kill the tumor [
51]. This concept has created considerable oncologic interest since numerous PI3K inhibitors are currently investigated and may be combined with DNA damaging agents. It is conceivable that PTEN PTM interfere with PI3K inhibition via determination of the cytosolic enzyme activity. A further question is to what degree such PTM would affect the ratio between intracellular PTEN and its secreted variant PTEN Long that may be bestowed to cancer cells from stroma or introduced biopharmaceutical.
Acknowledgements
We would like to thank Martina Storz, Silvia Behnke, Jasmine Roth and Doris Kradolfer for excellent technical assistance with construction of the TMA, IHC and FISH, respectively. Prof. B. Seifert and Dr. M. Roos, Institute of Social and Preventive Medicine, Biostatistics Unit, Hirschengraben 84, CH-8001 Zurich are kindly acknowledged for statistical advisory. Prof. H. Moch and Prof. A. Perren are acknowledged for critical reading of the manuscript. “Lungenliga Zürich” supported S.C. and W.W. for this work, while the Center for Clinical Research, University Hospital and University of Zurich supported A.S. (ref. nr. DFL1225).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
SC and AS participated in designing the study, collecting data, TMA scoring, computing statistical analysis and writing of the manuscript. VT participated in collecting data, TMA scoring and manuscript writing. AA participated in TMA preparation and scoring as well as data collection. TW participated in study design, TMA scoring and manuscript writing. PK and CO participated in TMA preparation and data collection. WW participated in study design and manuscript revision. All authors read and approved the final manuscript.